STATE OF THE ART
Neurobiological diseases affecting the cortex, such as Alzheimer, epilepsy, mental retardation, ADHD and autism, are a burden for society. Yet, drug development is impeded by the lack of animal models recapitulating the clinical features of these diseases.
There is thus a need for models of human neurobiological diseases in support to drug development processes.
The team of Pr. Vanderhaeghen developed a simple and efficient method to generate highly pure human, IPS cell-derived, cortical neuron preparations.
High purity is achieved by adding a newly identified proneurogenic factor, BCL6, during in vitro neuronal differentiation of IPS cells.
This method may be used in combination with the patented method (WO/2009/024448), also developed by the team of Pr. Vanderhaeghen, to generate human cortical neurons and in vitro models of human neuronal diseases from IPS cells.in vitro neuronal differentiation of IPS cells.
A patented method to produce highly pure, well-defined and disease-relevant human cortical neurons to use as reagent in support to drug development processes .
KEY ADVANTAGES OF THE TECHNOLOGY
Highly pure preparation of human cortical neurons
Differentiation into healthy cortical neurons
Differentiation into functional disease-relevant cortical neurons
MAIN PUBLICATIONS (related to this technology)
BCL6 induces neurogenesis through Sirt1-dependent epigenetic repression of selective Notch transcriptional targets. Tiberi, L., van den Ameele, J., Dimidschstein, J., Piccirilli, J., Gall, D., Herpoel, A., Bilheu, A., Bonnefont, J., Iacovino, M., Kyba, M., Bouschet T., and Vanderhaeghen P.
Nature Neurosci (2012) 15 : 1627-1635
An intrinsic mechanism of corticogenesis from embryonic stem cells. Gaspard N, Bouschet T, Hourez R, Dimidschstein J, Naeije G, van den Ameele J, Espuny-Camacho I, Herpoel A, Passante L, Schiffmann SN, Gaillard A, Vanderhaeghen P. Nature (2008) 455 : 351-357
Type of Business Relationship Sought
Partnership or license agreement
Last Updated Jun 2014